_____________________________________________________________________________________ Abingdon Health
Expansion in the US and innovative laboratory services fuel Abingdon Health’ s growth in the diagnostics industry
From its facilities in the US and UK, Abingdon Health( Abingdon) provides end-to-end lateral flow development, manufacturing and regulatory solutions all under one roof. Since our last conversation about a year ago, Abingdon has experienced significant growth. Chris Yates, Group Chief Commercial Officer, shares a brief update of what has been going on in the business over that time.
“ It has been a very busy 12 months for us, during which we have continued to grow, primarily through our significantly expanded proposition. As a full-service Contract Development and Manufacturing Organization( CDMO) and Contract Research Organization( CRO), we provide all the necessary services to guide customers from initial concept to commercial success in the in-vitro diagnostics space. Last year, we strengthened this proposition by acquiring two businesses in the regulatory sector: CS Life Sciences and IVDeology. Additionally, we invested in building out our own analytical performance lab in the UK, further rounding out our customer proposition. Alongside these developments, we expanded into the US market by providing a comprehensive service
We are a onestop shop, which gives us the ability to synchronize various workstreams
proposition in Madison, Wisconsin. Ultimately, these initiatives have led to a significant increase in the number of customers seeking our expertise to take their projects through to commercialization.”
Within the last year, Abingdon has been involved in several projects across many segments. Still, one particular area stands out as the most promising one for the long-term.“ We are seeing a surge of interest in the field of companion diagnostics, which involves using diagnostic tests alongside therapeutics. This is an area of specific expertise and specialism for us, but we have also noted increased interest and activity in other clinical fields, such as infectious diseases, animal health, food testing, and environmental testing. As a result, we have been working on a broad mix of projects with customers. However, I would highlight that companion diagnostics is the standout area where there has been the most significant uptick in interest from US customers, driven by our investments in that market. We are seeing much more collaboration with pharmaceutical and biotech companies, further expanding our opportunities,” Chris enlightens.
manufacturing-today. com 169